Oxidative stress and airway inflammation in severe exacerbations of COPD

E M Drost, K M Skwarski, J Sauleda, N Soler, J Roca, A Agusti, W MacNee


Background: A study was undertaken to assess both oxidative stress and inflammation in the lungs of patients with chronic obstructive pulmonary disease (COPD) during severe and very severe exacerbations compared with those with stable COPD, healthy smokers, and non-smokers. Two sites within the lungs were compared: the large airways (in sputum) and the peripheral airways (by bronchoalveolar lavage (BAL)).

Methods: BAL fluid cell numbers and levels of tumour necrosis factor (TNFα) and interleukin (IL)-8 were measured as markers of airway inflammation and glutathione (GSH) levels as a marker of antioxidant status. Nuclear translocation of the pro-inflammatory transcription factors nuclear factor-xB (NF-xB) and activator protein 1 (AP-1) were also measured by electromobility shift assay in BAL fluid leucocytes and lung biopsy samples.

Results: Influx of inflammatory cells into the peripheral airways during exacerbations of COPD was confirmed. Increased IL-8 levels were detected in BAL fluid from patients with stable COPD compared with non-smokers and healthy smokers, with no further increase during exacerbations. In contrast, IL-8 levels in the large airways increased during exacerbations. GSH levels were increased in the BAL fluid of smokers (44.4%) and patients with stable COPD (23.5%) compared with non-smokers and were reduced during exacerbations (severe 89.2%; very severe 52.3%) compared with stable COPD. NF-xB DNA binding in BAL leucocytes was decreased in healthy smokers compared with non-smokers (41.3%, n = 9, p < 0.001) but did not differ in COPD patients, whereas AP-1 DNA binding was significantly decreased during exacerbations of COPD.

Conclusion: There is evidence of increased oxidative stress in the airways of patients with COPD that is increased further in severe and very severe exacerbations of the disease. This is associated with increased neutrophil influx and IL-8 levels during exacerbations.

Glutathione (GSH) is the principal small molecular weight thiol in the lungs which, together with its redox enzymes, provides an important protective antioxidant system. Studies show depletion of GSH in lung cells in vitro and in rat lungs in vivo following acute exposure to cigarette smoke, with a rebound increase in levels over time.12 These findings are in agreement with the high levels of GSH reported in the epithelial lining fluid of smokers.14 Changes in GSH levels were found to be due to inhibition (by acute smoking) and then enhanced activation of the rate limiting enzyme for GSH production, gamma-glutamylcysteine synthetase (γ-GCS).15 The regulation of this gene was linked with the redox sensitive transcription factor, AP-1.16

Exacerbations of COPD are considered to reflect worsening of the underlying chronic inflammation in the airways. However, there is little information on the inflammatory responses in the lungs in exacerbations of COPD, particularly during severe exacerbations. Patients with COPD are known to have increased numbers of activated neutrophils in their airways. These neutrophils are believed to be attracted to the airways by the cytokines IL-8 and TNFα which are present in increased levels in the lungs of patients with stable COPD.1 Further increases in the levels of cytokines and also increased cell numbers in the large airways have been reported during exacerbations of the disease.2 Moreover, the frequency of

Abbreviations: AP-1, activator protein 1; COPD, chronic obstructive pulmonary disease; EMSA, electrophoretic mobility shift assay; γ-GCS, gamma-glutamylcysteine synthetase; GSH, glutathione; IL, interleukin; NF-xB, nuclear factor-xB; TNFα, tumour necrosis factor α.
exacerbations is associated with disease severity and a further increase in airways inflammation. These patients have a reduced quality of life and significantly more hospital admissions and a longer time in hospital, thereby adding to the socioeconomic burden.

The aim of this study was to assess the oxidant/antioxidant imbalance and markers of inflammation in both the proximal and distal compartments of the lungs in patients with severe and very severe exacerbations of COPD. It is known that samples from the different compartments of the lungs yield differences in cell numbers, markers of inflammation and oxidative stress. We therefore set out to assess the extent and location of inflammation in these patients. Specifically, we studied the antioxidant GSH, cell numbers, and the inflammatory mediators TNFα and IL-8 in proximal and distal airways.

METHODS

Study subjects

Three groups of patients with COPD were studied. A group with moderate COPD (GOLD stage II), diagnosed in accordance with GOLD guidelines, were studied when clinically stable at least 6 weeks after their last exacerbation, and two groups of patients with severe COPD were studied during exacerbations with severity assessed by healthcare utilisation according to the European Respiratory Society COPD guidelines. Exacerbations were defined as an increase in symptoms beyond normal day-to-day variation requiring a change in medication and hospital admission. According to a recent consensus statement on exacerbations, these patients could be divided into those with severe exacerbations (GOLD stage III) requiring hospital admission, and those with very severe exacerbations (GOLD stage IV) who had respiratory failure and required intervention with mechanical ventilation.

 Patients with severe or very severe exacerbations of COPD were studied within 48 hours of admission to hospital or the intensive care unit. Exclusion criteria were age less than 40 years; pneumonia or other lung diseases; a history suggestive of asthma; and treatment with oral corticosteroids, non-steroidal anti-inflammatory agents, or theophylline preparations during the 2 weeks before admission. Healthy non-smokers and smokers formed control groups for comparison. Smokers had not smoked for 12 hours before admission.

Subjects were given oxygen at 2 l/min throughout the procedure. Subjects were given oxygen at 2 l/min throughout the procedure. Two separate samples were obtained: (1) large airways secretions and (2) bronchoalveolar lavage (BAL) fluid from a segment of the middle lobe or lingula. Resident mucus was aspirated from the trachea and main bronchi to represent a large airways sample. The collection receptacle was then changed before BAL was performed using up to 240 ml warmed saline in 30 ml aliquots and aspirated immediately using a low suction rate. This technique samples the distal airways and alveoli.

A biopsy sample was taken from a segmental bronchus where possible and frozen immediately at −80°C. Biopsy specimens were homogenised in cytoplasmic extraction buffer containing 10% Nonidet-40 (NP40) as described for electrophoretic mobility shift assay (EMSA) and nuclear proteins extracted as detailed below.

Processing of proximal and distal airway samples

The sample of proximal large airway secretions was weighed and an equal volume of diethioctetol (DTT) (stock 1% in distilled water diluted to 0.1% in phosphate buffered saline (PBS)) was added. The sample was mixed on ice for 15 minutes, following which an equal volume of PBS was added and the solution filtered through 48 μm nylon gauze. The supernatant was centrifuged at a relative centrifugal force of 1050g for 10 minutes at 4°C. The cell pellet was discarded and aliquots of the spun supernatant were stored at −70°C.

BAL fluid from the distal airspaces was filtered through sterile gauze swabs and centrifuged at 242g for 10 minutes at 4°C. The supernatant was decanted and spun at 1050g for 10 minutes at 4°C and aliquoted for storage at −70°C for later analysis. The cell pellet obtained from the BAL fluid was washed in PBS and counted with a haemocytometer. Viability was ascertained by exclusion of trypan blue. Cytospins were prepared in a Shandon cytospin 3 (Shandon, Pittsburgh, PA, USA) and stained with Diff-Quick stain (Merz Dade, Switzerland). Cell differential counts were determined by counting 200 cells per sample.

Assays

All reagents were obtained from Sigma (Poole, UK) unless stated otherwise.

Glutathione

Reduced glutathione (GSH) was measured in BALF fluid by the method of Tietze with modifications for a 96 well plate. Large airway secretions were not assessed for GSH as the presence of DTT interferes with the GSH assay (by interacting with GSH reductase). The reaction rate of DTNB, NADPH, and GSH reductase was measured over 6 minutes at an absorbance of 410 nm using a Dynex MRX plate reader. A standard curve of GSH in the range of 0.25–16 μg/ml was used. The results were expressed as ng GSH/mg total protein, as measured by the Pierce bicinchoninic acid (BCA) protein assay (Pierce and Warriner (UK) Ltd, Chester, UK).

IL-8 and TNFα ELISAs

IL-8 and TNFα concentrations in large airway and BAL fluid samples were assessed by a human enzyme-linked immunosorbent sandwich assay (ELISA) using specific monoclonal biotinylated antibodies (R&D Systems, Oxon, UK) and a streptavidin peroxidase (Dako Ltd, Ely, UK)/5,5′,5′-tetramethylbenzidine (Boehringer Mannheim, East Sussex, UK) detection system. Sulphuric acid was added to terminate the reaction and the optical density was determined at 450 nm. Cytokine levels were expressed as pg/ml or ng/ml. For BAL fluid, the data were expressed per mg protein (as measured by the Pierce BCA protein assay) to account for the different volumes of saline instilled during lavage. DTT and lignocaine did not interfere with the ELISAs (data not shown).

Electrophoretic mobility shift assay (EMSA)

Nuclear proteins were extracted from mixed leucocytes obtained from BAL fluid and lung biopsies by the method of Andrews and Faller. The cells were incubated in

www.thoraxjnl.com
cytoplasmic extraction buffer (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT and 1 µg/ml leupeptin, 1 µg/ml aprotinin, 10 µg/ml pepstatin, 10 µM 4-(2-aminomethylbenzenesulfonyl fluoride)) for 15 minutes on ice and lysed with 10% Nonidet-40 (NP-40). After centrifugation the nuclei were resuspended in hypertonic nuclear extraction buffer (20 mM Hepes-KOH, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 25% glycerol containing 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 10 µM 4-(2-aminomethylbenzenesulfonyl fluoride, 10 µM glycerophosphate, 1 mM Na₃VO₄) for 20 minutes on ice. The samples were centrifuged and the supernatant stored at −70°C. Biopsy specimens were homogenised in cytoplasmic extraction buffer and the procedure followed as for BAL fluid leucocytes.

EMSA's were performed as previously described.27 Seven µg of nuclear protein (as determined using the Bio-Rad protein assay) were incubated in binding buffer (50 mM Tris-HCl, pH 7.0, 500 mM KCl, 5 mM DTT, 5 mM EDTA, 2.5 mM poly(dI-dC).poly(dI-dC) added per reaction) with 32P-ATP (Amersham, Buckinghamshire, UK) end labelled consensus oligonucleotides for NF-κB and AP-1 (Promega, Southampton, UK). The sequences of oligonucleotides used for EMSAs were: NF-κB sense 5'-AGTTGAGGAGCTTCCCCAGG-3', AP-1 sense 5'- CGGTTGATGATCGACGGAA-3'. Binding was allowed to proceed for 20 minutes at room temperature and electrophoresed on a 6% non-denatured polyacrylamide gel in 1X Tris-buffered-EDTA (TBE) buffer. Specificity was determined by 100 fold excess addition of a cold unlabelled corresponding oligonucleotide (cold competitor) and a different oligonucleotide (non-competitor). Gels were dried onto Whatman paper and exposed for autoradiography. The retarded oligonucleotides were visualised by a Storm 860 phosphoimager and the intensity of the NF-κB bands were quantified using ImageQuant Analysis (Molecular Dynamics Inc, Buckinghamshire, UK).

Table 1 Characteristics of subjects

<table>
<thead>
<tr>
<th></th>
<th>Non-smokers</th>
<th>Healthy smokers</th>
<th>Stable COPD</th>
<th>Severe exacerbations of COPD</th>
<th>Very severe exacerbations of COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>53.5 (2.5)</td>
<td>50.3 (2.1)</td>
<td>70.3 (5.4)</td>
<td>57.8 (3.5)</td>
<td>69.9 (1.6)</td>
</tr>
<tr>
<td>M/F</td>
<td>4/6</td>
<td>6/6</td>
<td>4/3</td>
<td>7/0</td>
<td>7/0</td>
</tr>
<tr>
<td>FEV₁ when stable (%)</td>
<td>116.3 (7.7)</td>
<td>98.5 (3.9)</td>
<td>63.7 (7.5)</td>
<td>28.6 (0.14)***</td>
<td>31.4 (6.9)***</td>
</tr>
<tr>
<td>Smoking (pack years)</td>
<td>NA</td>
<td>41 (6)</td>
<td>38 (12)</td>
<td>42.8 (6.5)**</td>
<td>46.0 (7.2)**</td>
</tr>
<tr>
<td>Paco₂/Paco₅ (kPa)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>52.5</td>
<td>58 (6)**</td>
</tr>
<tr>
<td>Oral corticosteroids (Y/N)</td>
<td>--/--</td>
<td>--/--</td>
<td>--/7</td>
<td>8.9 (0.4)/6.0 (0.3)</td>
<td>6.7 (1.4)/9.1 (1.1)</td>
</tr>
<tr>
<td>Inhaled corticosteroids (Y/N)</td>
<td>--/--</td>
<td>--/--</td>
<td>--/7</td>
<td>8/2</td>
<td>5/3</td>
</tr>
</tbody>
</table>

Values are shown as mean (SE).

FEV₁: forced expiratory volume in 1 second; FVC, forced vital capacity; PaO₂, PaCO₂, arterial oxygen and carbon dioxide tensions; NA, not applicable; ND, not done.

*p<0.05, **p<0.01, ***p<0.001 compared with non-smokers.

RESULTS

Subjects

Twenty one patients with COPD were studied: seven with moderate COPD were studied when stable, seven with a severe exacerbation, and seven with a very severe exacerbation of COPD and respiratory failure. Ten non-smokers and 12 smokers with no respiratory symptoms and normal spirometric data were studied for comparison. The characteristics of the subjects at the time of enrolment into the study are shown in table 1. All healthy subjects had normal lung function. Non-smokers and healthy smokers were younger than those with stable COPD and those with severe exacerbations. Patients with very severe exacerbations of COPD had a significantly greater number of pack years of smoking than healthy smokers (p<0.05), although all smokers had at least a 22 pack year history. Significant differences in % predicted forced expiratory volume in 1 second (FEV₁) and ratio of FEV₁ to forced vital capacity (FVC) are evident between the groups (table 1).
Table 2  Total and differential cell counts in bronchoalveolar lavage (BAL) fluid

<table>
<thead>
<tr>
<th></th>
<th>Non-smokers (n = 10)</th>
<th>Healthy smokers (n = 12)</th>
<th>Stable COPD (n = 7)</th>
<th>Severe exacerbations of COPD (n = 7)</th>
<th>Very severe exacerbations of COPD (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume saline recovered (ml)</td>
<td>60.0 (7.4)</td>
<td>47.2 (5.5)</td>
<td>15.3 (3.8)**††</td>
<td>42.2 (5.2)</td>
<td>27.5 (10.4)*</td>
</tr>
<tr>
<td>% recovery of saline</td>
<td>40.6 (4.2)</td>
<td>31.1 (3.8)</td>
<td>15.6 (2.4)**††</td>
<td>26.3 (3.4)</td>
<td>19.8 (6.8)*</td>
</tr>
<tr>
<td>Total cell count (x10⁷)</td>
<td>2.9 (0.6)</td>
<td>6.3 (1.3)</td>
<td>0.73 (0.6)**††</td>
<td>3.74 (0.8)</td>
<td>43.7 (38.4)**††</td>
</tr>
<tr>
<td>% Mononuclear (macrophage and lymphocyte)</td>
<td>95 (2.6)</td>
<td>94.5 (2.2)</td>
<td>80.6 (6.2)</td>
<td>63.7 (12.4)</td>
<td>49.1 (14.3)**††</td>
</tr>
<tr>
<td>% Neutrophils</td>
<td>4.8 (2.6)</td>
<td>4.9 (1.6)</td>
<td>17.9 (5.6)</td>
<td>41.4 (12.5)**††</td>
<td>50.7 (14.3)**††</td>
</tr>
<tr>
<td>% Eosinophils</td>
<td>0 (0.0)</td>
<td>0.3 (0.2)</td>
<td>0.6 (0.6)</td>
<td>0.1 (0.1)</td>
<td>0.3 (0.2)</td>
</tr>
</tbody>
</table>

Values are mean (SE).
*p < 0.05, ††p < 0.001 compared with non-smokers.
**p < 0.01 compared with smokers.
†p < 0.05 compared with severe COPD.
* †††p < 0.001 compared with very severe COPD.

BAL fluid cell counts

The percentage recovery of BAL fluid and differential cell counts for BAL fluid leucocytes are shown in table 2. Significantly less fluid was aspirated in patients with moderate and very severe COPD than in non-smokers. The total BAL fluid cell count was significantly reduced in patients with moderate COPD and was significantly higher in those with very severe COPD than in healthy smokers and non-smokers, respectively. Patients with an exacerbation of COPD had increased numbers of neutrophils in the BAL fluid compared with healthy smokers and non-smokers. A concomitant decrease in mononuclear cells was seen in patients with very severe COPD. Moreover, the percentage of neutrophils present in the BAL fluid had a linear relationship with the FEV₁/FVC ratio (r = −0.751, n = 34, p < 0.0001; fig 1).

Measurements of oxidative stress

Healthy smokers had considerably higher GSH levels than non-smokers or the COPD patient groups (fig 2). GSH levels in patients with COPD were significantly lower than in healthy smokers but were still higher than in healthy non-smokers, with an even greater reduction observed during acute exacerbations.

Inflammatory mediators

TNFα and IL-8 levels were measured in large airway secretions and BAL fluid. TNFα levels detected in airway secretions and BAL fluid were generally low and were not significantly different between the groups for either large airway secretions or BAL fluid (data not shown). Significantly higher levels of IL-8 were detected in large airway secretions during both severe and very severe exacerbations of COPD (fig 3A). Significantly higher levels of IL-8 were observed in the BAL fluid in all COPD patients, although the levels during exacerbations did not differ from those in stable patients (fig 3B). IL-8 levels in large airway secretions had a linear relationship with the FEV₁/FVC ratio (r = −0.592, p < 0.01, n = 29; fig 4A); a similar relationship was seen in BAL fluid (r = −0.33, n = 35, p = 0.05; fig 4B).

Figure 3  Assessment of inflammation in the airways. IL-8 levels were determined in (A) large airway secretions and (B) BAL fluid for the different subject groups. Data are expressed as medians with interquartile range (box) and range (whiskers); numbers of subjects are shown in brackets. ANOVA values were p < 0.01 for large airway secretions and p < 0.001 for BAL fluid; †p < 0.05, ††p < 0.01 v non-smokers (multiple comparison post testing).

Figure 2  Assessment of oxidative stress locally in the lungs. Increased levels of glutathione (GSH) were seen in BAL fluid from asymptomatic smokers. Patients with moderate COPD were studied in a stable condition and patients with moderate or severe COPD were studied during an exacerbation. Data are expressed as medians with interquartile range (box) and range (whiskers); numbers of subjects shown in brackets. ANOVA p < 0.0001; ††p < 0.01 and †††p < 0.001 v non-smokers; †p < 0.05, †††p < 0.001 v smokers; ††p < 0.01 v subjects with severe COPD exacerbations (multiple comparison post testing).

Transcription factor nuclear translocation of NF-κB in lung biopsies and BAL leucocytes

Transcription factor DNA binding was assessed for nuclear proteins isolated from both bronchial biopsy specimens and
Inflammation and oxidative stress in COPD

Evident in the large airways (large airways and BAL fluid. A significant linear relationship was observed between IL-8 levels and the FEV1/FVC ratio as assessed by the FEV1/FVC ratio. This increase in neutrophil numbers is concomitant with an increase in IL-8 levels in the proximal airway secretions in patients with stable and exacerbated COPD compared with smokers and non-smokers, and an increase in IL-8 levels in the distal airspaces in exacerbations of COPD. A new finding in this study is the depletion of GSH in the airspaces in exacerbations of COPD, indicating increased oxidative stress.

Although the pathological events that lead to the development of airways obstruction and exacerbations in COPD are still not completely understood, inflammation of the airways appears to be a critical factor. Indeed, by examining lung tissue sections, Hogg and colleagues found an increase in airways inflammation evidenced by the enhanced presence of mucous exudates and inflammatory leucocytes—to be associated with COPD disease severity. Oxidative stress is thought to be an important component of inflammation through the activation of oxidant sensitive transcription factors leading to increased transcription of pro-inflammatory genes. Critical to the effects of oxidative stress is the protective counterbalance of antioxidant systems. A shift in this oxidant/antioxidant balance could result in an increase in oxidative stress which may cause cellular damage. In this regard, GSH appears to be an important antioxidant in the lungs and is present in high concentrations in epithelial lining fluid.

**DISCUSSION**

Increased neutrophils were found in the distal airspaces of patients with COPD, which increased further during exacerbations of the disease. The percentage of neutrophils in the distal airspace had a negative linear relationship with the severity of airways obstruction as assessed by the FEV1/FVC ratio. This increase in neutrophil numbers is concomitant with an increase in IL-8 levels in the proximal airway secretions in patients with stable and exacerbated COPD compared with smokers and non-smokers, and an increase in IL-8 levels in the distal airspaces in exacerbations of COPD. A new finding in this study is the depletion of GSH in the airspaces in exacerbations of COPD, indicating increased oxidative stress.

Although the pathological events that lead to the development of airways obstruction and exacerbations in COPD are still not completely understood, inflammation of the airways appears to be a critical factor. Indeed, by examining lung tissue sections, Hogg and colleagues found an increase in airways inflammation evidenced by the enhanced presence of mucous exudates and inflammatory leucocytes—to be associated with COPD disease severity. Oxidative stress is thought to be an important component of inflammation through the activation of oxidant sensitive transcription factors leading to increased transcription of pro-inflammatory genes. Critical to the effects of oxidative stress is the protective counterbalance of antioxidant systems. A shift in this oxidant/antioxidant balance could result in an increase in oxidative stress which may cause cellular damage. In this regard, GSH appears to be an important antioxidant in the lungs and is present in high concentrations in epithelial lining fluid.

**Figure 4** Relation between IL-8 levels and the FEV1/FVC ratio in (A) the large airways and (B) BAL fluid. A significant linear relationship was evident in the large airways and BAL fluid. *r*=−0.592, *n*=29, *p*<0.001 for IL-8 and *r*=−0.33, *n*=35, *p*<0.0001 for BAL fluid.

**Figure 5** Electrophoretic mobility shift assays (EMSAs) for (A) NF-κB and (B) AP-1 DNA binding in BAL fluid leucocytes. Data are expressed as means (SE) values or as medians with interquartile range (box) and range (whiskers) for the different subject groups; numbers of subjects are shown in brackets. Measurements for patients with stable COPD are not shown as DNA binding was only assessed in two samples for this group. ANOVA values were *p*<0.05 for NF-κB and *p*<0.05 for AP-1; *** *p*<0.001; ** *p*<0.01; * *p*<0.05; controls; *p*<0.05 v healthy smokers (multiple comparison testing).
equivalent to levels detected during exacerbations suggests that the lower cell numbers in stable COPD is not due to difficulty in retrieving the lavage fluid. Furthermore, the highest cell counts recovered were for patients with very severe COPD where lavage fluid recovery is also low.

Although increased total cell counts and increased percentage neutrophils in sputum and BAL fluid have been reported previously, few studies have assessed inflammation in the airways during acute exacerbations of COPD. Qiu and colleagues reported increased neutrophil recruitment and gene expression of neutrophil chemoattractant (CXC) receptors in bronchial biopsies from patients with acute severe exacerbations of COPD compared with those with stable COPD and non-smoking healthy subjects. Aaron and colleagues measured sputum TNFα and IL-8 levels during exacerbations and found them to be significantly increased. Bhowmik et al examined sputum inflammatory markers in stable subjects who had frequent exacerbations and reported increased levels of IL-8 and IL-6 and total cell counts. In addition, more sputum and greater purulence of sputum was found over time during exacerbations, suggesting the presence of more inflammation over time. Previous reports in patients with mild exacerbations have shown an increase in eosinophil numbers that was not seen in our study of severe exacerbations of COPD. It should be noted that the patients in our study groups were not age matched, and those with moderate COPD and very severe COPD were significantly older than non-smokers and healthy smokers. This was unavoidable as the COPD patients attending the Royal Infirmary in Edinburgh constitute an older age group and the healthy individuals willing to participate in the study are not generally so elderly.

A role for IL-8 in the recruitment to and activation of neutrophils in the airways of patients with COPD has been proposed as it is detected in sputum and BAL fluid from patients with COPD. Although Yamamoto et al found a negative correlation between IL-8 levels in sputum and FEV1/FVC in patients with stable COPD, we were unable to confirm that IL-8 levels are increased in large airway secretions from patients with moderate stable COPD but we did find increased IL-8 levels in the distal airspaces. Increased IL-8 levels and neutrophil numbers in BAL fluid have previously been reported in patients with stable COPD. No significant difference was found in TNFα levels in either large airway secretions or BAL fluid (data not shown). However, it should be noted that the DTT used to break up the sputum mucin can interfere with the measurement of TNFα by ELISA which might explain our lack of a result. Interestingly, IL-8 levels in both large airways secretions and BAL fluid had a negative linear relationship with the severity of airways obstruction as measured by the FEV1/FVC ratio. It should be noted that these correlations were performed on all subjects—not just patients with COPD—because of the small numbers in individual groups. We found no evidence of a linear relationship between the percentage neutrophils and IL-8 levels in BAL fluid; however, such a relationship has been reported by other workers. These data therefore suggest that the IL-8 level may be useful as an indicator of disease severity and that, in addition to IL-8, other factors such as leukotriene B4 may be responsible for the neutrophil influx in exacerbations and stable COPD.

It has been reported that the IL-8 gene has both NF-κB and AP-1 binding sites in the promoter region that regulates its transcriptional activation. Both NF-κB and AP-1 are oxidant sensitive transcription factors that have been implicated in the regulation of numerous pro-inflammatory mediators pertinent to lung inflammation. We therefore assessed the nuclear translocation of NF-κB in bronchial biopsies and also in BAL fluid leucocyte populations. No significant difference in nuclear localisation of NF-κB was found in bronchial biopsies, although a trend was evident for increased NF-κB DNA binding in healthy smokers and patients with COPD. In contrast, BAL fluid leucocytes from healthy smokers showed a significant reduction in NF-κB DNA binding compared with non-smokers, while nuclear translocation of NF-κB during exacerbations of COPD did not differ from that in non-smokers. Since we obtained enough BAL fluid leucocytes from only two patients with stable COPD to determine NF-κB nuclear translocation (data not shown), we were unable to make a comparison with samples obtained during exacerbations. However, we have previously reported a comparison of NF-κB DNA binding in sputum leucocytes from patients with stable and acute exacerbations of COPD and found a significant increase during exacerbations. There are reports in the literature of both increased and decreased NF-κB activity for cigarette smoke exposure in vitro. Cigarette smoke exposure in vitro reduced peripheral blood monocyte NF-κB DNA binding activity.

A possible explanation for the reduced NF-κB DNA binding in BAL fluid leucocytes may be the excessive production of oxidants such as hydrogen peroxide and nitric oxide during exacerbations which inactivate inhibitory kinas (Ik-kinase; IKK), the enzyme responsible for the phosphorylation of IkBα, resulting in its degradation and activation of NF-κB. Alternatively, the lower levels of NF-κB DNA binding observed in BAL fluid leucocytes from healthy smokers may relate to the higher levels of antioxidants offering protection against oxidant stress by inhibiting NF-κB activation and translocation to the nucleus, leading to less gene activation.

In accordance with the latter, and as previously reported, we found higher levels of the antioxidant GSH in BAL fluid in smokers. We now report, for the first time, the levels of GSH in the distal airspaces of patients with COPD. Patients with stable COPD had higher levels of normal GSH levels in the BAL fluid which became depleted during exacerbations of the disease. The lower levels of GSH found in smokers with COPD compared with healthy smokers could

---

**Table 3** DNA binding of transcription factors NF-κB and AP-1 in lung biopsy specimens

<table>
<thead>
<tr>
<th></th>
<th>Non-smokers</th>
<th>Healthy smokers</th>
<th>Stable COPD</th>
<th>Very severe exacerbations of COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-κB</td>
<td>29.7 (22.0–108.7)</td>
<td>116.3 (64–199.7)</td>
<td>74.9 (45.9–127.4)</td>
<td>34.1 (6.7–103.1)</td>
</tr>
<tr>
<td>AP-1</td>
<td>12.6 (0–40.0)</td>
<td>–</td>
<td>18.8 (16.5–21.2)</td>
<td>40.5 (32.6–48.3)</td>
</tr>
</tbody>
</table>

Data shown as median (IQR) values.

No biopsy specimens were obtained from patients with severe exacerbations of COPD.

No significant difference was detected between the groups for either NF-κB or AP-1.
facilitate NF-kB activation leading to inflammation, which is evident in the increased neutrophil numbers and IL-8 levels in the BAL fluid.

In healthy smokers, and possibly in patients with stable COPD, the increased GSH levels in response to oxidative stress are associated with an enhanced expression of γ-glutamylcysteine synthetase (γ-GCS), the main enzyme in the synthesis of GSH. In contrast, the reduced GSH levels in acute exacerbations may reflect an insufficient response to oxidative stress in the form of reduced γ-GCS activity resulting in lower GSH levels or direct depletion by an overwhelming oxidative burden from reactive oxygen species released by activated neutrophils. Support for the former mechanism comes from the observed decrease in DNA binding of the transcription factor AP-1 which regulates γ-GCS in exacerbations of COPD. The rate limiting enzyme for GSH synthesis, was previously found to be downregulated in lung epithelial cells following acute exposure to cigarette smoke with a concomitant depletion of GSH. With inadequate protection, the lung tissue in these patients could be predisposed to injury. Indeed, in a study by Koul and colleagues, a decrease in lung GSH levels in mice exposed to cigarette smoke was associated with an increase in lipid peroxidation products. Assessment of lipid peroxidation markers in exhaled breath condensate also revealed an increase in patients with COPD compared with healthy smokers and non-smokers. Taken together, these data suggest an important role for GSH in the prevention of peroxidative lung damage in patients with COPD.

In conclusion, our data suggest that there is impaired antioxidant status in the peripheral airways of patients with stable COPD which is more pronounced in exacerbations. This is reflected in the presence of an inflammatory response, as shown by an increase in cell numbers and cytokine levels. A comparison of the parameters measured for very severe exacerbations compared with severe exacerbations of COPD revealed an increase only in the number of leucocytes in BAL fluid.

ACKNOWLEDGEMENTS

The authors thank all the subjects who participated in the study.

Authors’ affiliations

E M Drost, W MacNee, ELEGIC/Colt Laboratory, Centre for Inflammation Research, University of Edinburgh, Medical School, Edinburgh EH8 9AG, UK
K M Skwarski, W MacNee, Royal Infirmary Edinburgh, Little France, Edinburgh EH16 4SA, UK
J Sauleda, A Agustí, Servei de Pneumologia and Unitat d’investigació, Hospital Universitari Son Duret, Palma de Mallorca, Spain
N Soler, J Roca, Servei de Pneumologia (ICPCT), Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain

The study was funded by Novartis Pharmaceutical Company, Horsham, UK, and part funded by FIS 00/0281 and Red Respira (RTIC C03/011 Fondo de Investigacion Sanitaria).

REFERENCES

1 Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449–53

www.thoraxjnl.com


LUNG ALERT

Induced sputum for the diagnosis of paediatric pulmonary TB


Sputum induction in adults is a well recognised method of diagnosing pulmonary tuberculosis (TB). However, in children this technique is not regarded as feasible since young children tend to swallow their sputum and do not expectorate. Gastric lavage has been used to obtain microbiological confirmation in children but this requires an overnight fast, repeated specimens, and admission to hospital.

This 2 year study carried out in Cape Town, South Africa compared the yield of Mycobacterium tuberculosis from repeated induced sputum samples with that from gastric lavage in young children from an area with a high rate of HIV and TB. 250 children with suspected TB were studied, the median age being 13 months. A positive smear or culture was obtained from 62 children (25%). Samples from induced sputum and gastric lavage were positive in 54 (87%) and 40 (65%), respectively. Microbiological yield did not differ between HIV infected and HIV uninfected children. Sputum induction was well tolerated, with minor side effects of increased cough, epistaxis, vomiting, and wheeze.

This study shows that sputum induction is safe and useful for microbiological confirmation of pulmonary TB in infants and young children. The authors conclude that this technique is preferable to gastric lavage.

M Wijesinghe
SpR in Respiratory Medicine, Royal United Hospital, Bath, UK; memew@doctor.com